Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 133-141 , April 2010

Adverse effects of drugs on small intestine and colon

  • Zeino Zeino (Specialist Registrar in Gastroenterology)
    • ,
  • Guy Sisson (Research Specialist Registrar in Gastroenterology)
    • ,
  • Ingvar Bjarnason (Professor of Digestive Diseases)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 2032998768; fax: +44 2032996474.

References 

  1. Geboes K, Hertogh GD, Ectors N. Drug-induced pathology in the large intestine. Curr Diagn Pathol. 2006;12:239–247
  2. Bjarnason I, Hayllar J, Macpherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology. 1993;104:1832–1847
  3. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124:288–292
  4. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1992;327:749–754
  5. Bjarnason I, Zanelli G, Smethurst P, et al. Clinico-pathological features of nonsteroidal antiinflammatory drug induced small intestinal strictures. Gastroenterology. 1988;94:1070–1074
  6. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;1040–1045
  7. Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44:544–549
  8. Carson J, Notis WM, Orris ES. Colonic ulceration and bleeding during diclofenac therapy. N Engl J Med. 1990;323:135
  9. Halter F, Weber B, Huber T, et al. Diaphragm disease of the ascending colon associated with sustained release diclofenac. J Clin Gastroenterol. 1993;16:74–80
  10. Huber T, Ruchti C, Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology. 1992;100:1119–1122
  11. Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut. 1998;43:506–511
  12. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:301–314
  13. Vane JR. Towards a better aspirin. Nature. 1994;367:215–216
  14. Vane JR. NSAIDs, COX-2 inhibitors, and the gut. Lancet. 1995;346:1105–1106
  15. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665–674
  16. Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol. 2007;913–919
  17. Lichtenberger LM, Wang Z-M, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995;1:154–158
  18. Mahmud T, Rafi SS, Scott DL, et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum. 1996;39:1998–2003
  19. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706–714
  20. Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol. 2001;15:691–703
  21. Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–1178
  22. Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces inflammation and blood loss in NSAID enteropathy. Gut. 1992;33:1204–1208
  23. Hayllar J, Price AB, Smith T, et al. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss: effect of sulphasalazine and other disease modifying drugs. Arthritis Rheum. 1994;37:1146–1150
  24. Bjarnason I, Hayllar J, Somasundaram S, et al. Misoprostol in the treatment of NSAID-induced enteropathy: a double blind, placebo-controlled, parallel group study. Gastroenterology. 1993;104:A669
  25. Bjarnason I, Zanelli G, Prouse P, et al. Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet. 1987;2:711–714
  26. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulcer disease. Gut. 1987;28:527–532
  27. Campbell K, Steele RJC. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case control study. Br J Surg. 1991;78:190–191
  28. Corder A. Steroids, non-steroidal anti-inflammatory drugs and serious complications of diverticular disease. Br Med J. 1987;295:1238
  29. Coutrot S, Roland D, Barbier J, et al. Acute perforation of colonic diverticula associated with short term indomethacin. Lancet. 1978;2:1055–1056
  30. Cornish JA, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103:2394–2400
  31. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut. 1995;37:668–673
  32. Behrens R, Devereaux M, Hazleman B, et al. Investigation of auranofin-induced diarrhoea. Gut. 1986;27:59–65
  33. Tallón Aguilar L, Casado Maestre MD, López Bernal F, et al. Perforation of hollow viscera associated with cocaine use. Gastroenterol Hepatol. 2008;31:624
  34. Trinca KD, DeGennaro VA, Spector S, et al. Crack cecum. J Am Coll Surg. 2008;207:612
  35. Ellis CN, McAlexander WW. Enterocolitis associated with cocaine use. Dis Colon Rectum. 2005;48:2313–1216
  36. Marteau P, Flourié B, Froguel E, et al. Proctitis following the prolonged use of dextropropoxyphene and paracetamol suppositories: the risk persists despite change of excipient. Gastroenterol Clin Biol. 1990;14:102–103
  37. Wörmann B, Höchter W, Seib HJ, et al. Ergotamine-induced colitis. Endoscopy. 1985;17:165–166
  38. Vincens M, Ganansia R, du Puy-Montbrun T, et al. Necrotizing anorectitis and proctitis after long term utilization of a dextropropoxyphene and paracetamol association in suppositories, 7 cases. Therapie. 1982;37:321–326
  39. Lloyd-Still JD, Beno DW, Kimura RM. Cystic fibrosis colonopathy. Curr Gastroenterol Rep. 1999;1:231–237
  40. Spada C, Riccioni ME, Marchese M, et al. Isotretinoin-associated pan-enteritis. J Clin Gastroenterol. 2008;42:923–925
  41. Bjarnason I, Takeuchi K, Bjarnason A, et al. The G.U.T. of gut. Scand J Gastroenterol. 2004;39:807–815
  42. Hey HS, chmedes A, Nielsen AA, et al. Effects of five different alcoholic drinks on patients with Crohn's disease. Scand J Gastroenterol. 2007;42:968–972
  43. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–659
  44. Cheng J, Vemula N, Gendler S. Small bowel obstruction caused by intramural hemorrhage secondary to anticoagulant therapy. Acta Gastroenterol Belg. 2008;71:342–344
  45. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5:1559–1565
  46. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995;13:1303–1311
  47. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995;13:210–221
  48. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol. 1998;16:2745–2751
  49. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914
  50. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047
  51. Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res. 2004;10:6522–6527
  52. Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006;24(2):656–656
  53. Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol. 1993;11:148–151
  54. Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol. 2001;12:227–229
  55. Sharma RK. Vincristine and gastrointestinal transit. Gastroenterology. 1988;95:1435–1436
  56. Schnoll-Sussman F, Kurtz RC. Gastrointestinal emergencies in the critically ill cancer patient. Semin Oncol. 2000;27:270–283
  57. Avigan D, Richardson P, Elias A, et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998;83:409–414
  58. Wade DS, Nava HR, Douglass HO. Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer. 1992;1:17–23
  59. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35

PII: S1521-6918(10)00022-3

doi: 10.1016/j.bpg.2010.02.008

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 133-141 , April 2010

Article Tools

* Image Usage & Resolution